MX2024002696A - Derivados del acido 2-amino-5,5-dimetilhexanoico como moduladores de sortilina para su uso en el tratamiento de enfermedades del sistema nervioso central. - Google Patents

Derivados del acido 2-amino-5,5-dimetilhexanoico como moduladores de sortilina para su uso en el tratamiento de enfermedades del sistema nervioso central.

Info

Publication number
MX2024002696A
MX2024002696A MX2024002696A MX2024002696A MX2024002696A MX 2024002696 A MX2024002696 A MX 2024002696A MX 2024002696 A MX2024002696 A MX 2024002696A MX 2024002696 A MX2024002696 A MX 2024002696A MX 2024002696 A MX2024002696 A MX 2024002696A
Authority
MX
Mexico
Prior art keywords
treatment
modulators
nervous system
central nervous
sortilina
Prior art date
Application number
MX2024002696A
Other languages
English (en)
Spanish (es)
Inventor
Paul Brian Little
Manuel Javier Cases-Thomas
Mads Fuglsang Kjolby
Anders Nykjaer
Original Assignee
INSUSENSE ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INSUSENSE ApS filed Critical INSUSENSE ApS
Publication of MX2024002696A publication Critical patent/MX2024002696A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024002696A 2021-09-03 2022-09-02 Derivados del acido 2-amino-5,5-dimetilhexanoico como moduladores de sortilina para su uso en el tratamiento de enfermedades del sistema nervioso central. MX2024002696A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21194937.5A EP4144352A1 (en) 2021-09-03 2021-09-03 2-amino-5,5-dimethylhexanoic acid derivatives as sortilin modulators for use in the treatment of disease of the central nervous system
PCT/EP2022/074536 WO2023031440A1 (en) 2021-09-03 2022-09-02 2-amino-5,5-dimethylhexanoic acid derivatives as sortilin modulators for use in the treatment of disease of the central nervous system

Publications (1)

Publication Number Publication Date
MX2024002696A true MX2024002696A (es) 2024-05-14

Family

ID=77640524

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024002696A MX2024002696A (es) 2021-09-03 2022-09-02 Derivados del acido 2-amino-5,5-dimetilhexanoico como moduladores de sortilina para su uso en el tratamiento de enfermedades del sistema nervioso central.

Country Status (10)

Country Link
US (1) US20250268854A1 (cg-RX-API-DMAC7.html)
EP (2) EP4144352A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024537619A (cg-RX-API-DMAC7.html)
KR (1) KR20240056551A (cg-RX-API-DMAC7.html)
CN (1) CN118019533A (cg-RX-API-DMAC7.html)
AU (1) AU2022339056A1 (cg-RX-API-DMAC7.html)
CA (1) CA3229686A1 (cg-RX-API-DMAC7.html)
IL (1) IL311208A (cg-RX-API-DMAC7.html)
MX (1) MX2024002696A (cg-RX-API-DMAC7.html)
WO (1) WO2023031440A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250345446A1 (en) 2022-06-23 2025-11-13 Draupnir Bio Aps Bifunctional molecules that selectively induce degradation of extracellular targets in lysosomes
EP4342530A1 (en) * 2022-09-02 2024-03-27 Insusense ApS Sortilin modulators
EP4428122A1 (en) * 2023-03-07 2024-09-11 Vesper Bio Aps Sortiline modulators
EP4719366A1 (en) 2023-05-26 2026-04-08 Bertram Wiedenmann Sortilin inhibitors for treatment of patients with functional neuroendocrine tumors
TW202600557A (zh) * 2024-02-20 2026-01-01 日商大塚製藥股份有限公司 作為sort1抑制劑之哌啶-及嗎啉-羧酸鹽化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL300841A (cg-RX-API-DMAC7.html) * 1962-11-27 1900-01-01
JP4189108B2 (ja) * 1999-12-06 2008-12-03 株式会社トクヤマ アミノ酸エステル塩酸塩の製造方法
RU2312861C2 (ru) * 2002-03-05 2007-12-20 Мерк Фросст Кэнада Лтд. Ингибиторы катепсин-цистеинпротеазы
WO2008054475A2 (en) * 2006-03-13 2008-05-08 The Trustees Of Columbia University In The City Of New York Neuraminidase inhibitors and uses thereof
EP2262370A4 (en) * 2008-04-01 2011-08-31 Virobay Inc DIFLUOROUS COMPOUNDS AS A CYSTONE PROTEASE INHIBITOR
US9682967B2 (en) * 2013-01-28 2017-06-20 H. Lundbeck A/S N-substituted-5-substituted phthalamic acids as sortilin inhibitors
US20160331746A1 (en) 2015-05-12 2016-11-17 University Of South Florida Sortilin-Binding Small Molecules for Increasing Glucose Uptake
MX389001B (es) * 2015-10-23 2025-03-20 Navitor Pharm Inc Moduladores de interacción de sestrina-gator2 y sus usos.
ES3040534T3 (en) * 2017-04-26 2025-11-03 Navitor Pharm Inc Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression
EP4073116A1 (en) 2019-12-10 2022-10-19 Aarhus Universitet Compounds for treatment of eye diseases
EP3981394A1 (en) * 2020-10-07 2022-04-13 Insusense ApS A sortilin antagonist for use in the prevention or treatment of hearing loss.

Also Published As

Publication number Publication date
IL311208A (en) 2024-05-01
KR20240056551A (ko) 2024-04-30
EP4144352A1 (en) 2023-03-08
AU2022339056A1 (en) 2024-03-21
CA3229686A1 (en) 2023-03-09
EP4395776A1 (en) 2024-07-10
JP2024537619A (ja) 2024-10-16
CN118019533A (zh) 2024-05-10
US20250268854A1 (en) 2025-08-28
WO2023031440A1 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
BR112022024120A2 (pt) Derivado de piridina-pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo
BR112019024831A2 (pt) composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3
BR112015016911A2 (pt) tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn
BR112021026820A2 (pt) Inibidores heterocíclicos de monoacilglicerol lipase (magl)
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
EA201270666A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
CO2022016899A2 (es) Moduladores de il-17a
EA201500050A1 (ru) Бифтордиоксалан-амино-бензимидазольные ингибиторы киназы для лечения рака, аутоиммунного воспаления и нарушений цнс
BR112012024712A2 (pt) antagonistas do receptor vaniloide trpv1 com uma porção bicíclica
MX393982B (es) Nuevos derivados heteroaryl amida como inhibidores selectivos de histona deacetilasa 1 y 2 (hdac1/2).
CO2022018636A2 (es) Moduladores de il-17a
BR112017026159A2 (pt) inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer
EP2572711A4 (en) MEDICAMENT AGAINST MALARIA WITH 5-AMINOLEVULINIC ACID OR A DERIVATIVELY AS AN ACTIVE AGENT
BR112023000588A2 (pt) Derivados de piridazina como inibidores de alk5 e/ou alk4
BR112015022577A2 (pt) moduladores ship1 e métodos relacionados a esse
EP3819298A4 (en) COMPOSITION WITH TRKA INHIBITIVE EFFECT AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR RELIEF OF PAIN THEREOF AS AN ACTIVE SUBSTANCE
DOP2019000076A (es) DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112022010251A2 (pt) Derivados de benzilamida como inibidores do receptor i/alk5 do fator de transformação de crescimento beta
CO2024006728A2 (es) Derivados del ácido 3-fenil-1-benzotiofeno-2-carboxílico como inhibidores de la quinasa deshidrogenasa de alfa cetoácidos de cadena ramificada para el tratamiento de la diabetes, enfermedades renales, nash e insuficiencia cardiaca
BR112015019919A2 (pt) compostos bicíclicos
MX2023003846A (es) Compuesto de bifenilo como inmunomodulador, metodo de preparacion del mismo y aplicacion del mismo.
EP4635494A3 (en) AMIDO HETERO-ROMATIC COMPOUNDS
MX2024010344A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
CO2022007273A2 (es) Análogos de insulina novedosos y usos de estos